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Introduction {#his13498-sec-0004}
============

Breast cancer is the most frequently diagnosed cancer in women. It is also a predominant cause of mortality, and the global burden of breast cancer rises every year.[1](#his13498-bib-0001){ref-type="ref"} Approximately 10--20% of breast tumours belong to the triple‐negative (TN) subtype, defined by lack of expression of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which are companion biomarkers and/or therapeutic targets of hormone and anti‐HER2 therapy. Cytotoxic chemotherapy is the standard‐of‐care therapy, and is very effective in a subset of patients, but responses are not durable in all cases,[2](#his13498-bib-0002){ref-type="ref"} which ultimately relapse with the shortest progression‐free and overall survival of all breast cancers.[3](#his13498-bib-0003){ref-type="ref"} Accordingly, efforts are ongoing to identify predictive markers of chemotherapy efficacy in TN breast cancer (TNBC), as well as alternative treatments for patients who are most likely to develop resistance.

High‐resolution genetic and cellular profiling of TNBCs has revealed subgroups characterised by chromosomal instability (CIN), DNA repair defects, and androgen receptor (AR) signalling.[4](#his13498-bib-0004){ref-type="ref"}, [5](#his13498-bib-0005){ref-type="ref"}, [6](#his13498-bib-0006){ref-type="ref"} The immune microenvironment is also a strong determinant of both the molecular profile and the clinical outcome in TNBC patients, with the poorest prognostic group being characterised by stromal restriction of tumour‐infiltrating lymphocytes (TILs), or a general deficiency of TILs in tumour and stromal compartments.[7](#his13498-bib-0007){ref-type="ref"}, [8](#his13498-bib-0008){ref-type="ref"}, [9](#his13498-bib-0009){ref-type="ref"} Therapeutic strategies retargeting the immune system to cancer cells have proven successful in liquid cancers[10](#his13498-bib-0010){ref-type="ref"}, [11](#his13498-bib-0011){ref-type="ref"}, [12](#his13498-bib-0012){ref-type="ref"}, [13](#his13498-bib-0013){ref-type="ref"} as well as in a few solid tumours.[14](#his13498-bib-0014){ref-type="ref"}, [15](#his13498-bib-0015){ref-type="ref"}, [16](#his13498-bib-0016){ref-type="ref"}, [17](#his13498-bib-0017){ref-type="ref"}, [18](#his13498-bib-0018){ref-type="ref"} This is achieved by manipulating the endogenous immune response[19](#his13498-bib-0019){ref-type="ref"}, [20](#his13498-bib-0020){ref-type="ref"}, [21](#his13498-bib-0021){ref-type="ref"}, [22](#his13498-bib-0022){ref-type="ref"} and/or bypassing it altogether by genetically reprogramming T cells with adoptive transfer of chimeric antigen receptor (CAR) T cells, which are reprogrammed to target tumour antigens.[10](#his13498-bib-0010){ref-type="ref"}, [11](#his13498-bib-0011){ref-type="ref"}, [12](#his13498-bib-0012){ref-type="ref"}, [13](#his13498-bib-0013){ref-type="ref"}, [14](#his13498-bib-0014){ref-type="ref"}, [15](#his13498-bib-0015){ref-type="ref"}, [16](#his13498-bib-0016){ref-type="ref"}, [17](#his13498-bib-0017){ref-type="ref"}, [18](#his13498-bib-0018){ref-type="ref"} Therapeutic cancer vaccines may also be useful as part of regimens aimed at boosting antitumour immunity. Cancer vaccines and CAR T cells can be directed against proteins expressed by many cancers (shared antigens) or neoantigens encoded by mutant transcripts.

Cancer/testis antigens (CTAs) belong to a group of proteins that are expressed in the developing embryo, are restricted to the testis in the adult, and are aberrantly re‐expressed in malignancy, particularly high‐grade and advanced‐stage tumours, including TNBC.[23](#his13498-bib-0023){ref-type="ref"}, [24](#his13498-bib-0024){ref-type="ref"}, [25](#his13498-bib-0025){ref-type="ref"}, [26](#his13498-bib-0026){ref-type="ref"}, [27](#his13498-bib-0027){ref-type="ref"}, [28](#his13498-bib-0028){ref-type="ref"} Members of the melanoma‐associated antigen (MAGE) family and New York Esophageal Squamous Cell Carcinoma‐1 (NY‐ESO‐1) are among the CTAs being actively investigated as cancer immunotherapy targets. They have been shown to evoke spontaneous cytotoxic T‐cell responses in melanoma, oesophageal carcinoma, bladder cancer, and non‐small‐cell lung carcinoma.[29](#his13498-bib-0029){ref-type="ref"}, [30](#his13498-bib-0030){ref-type="ref"} Several studies have evaluated MAGE‐A and NY‐ESO‐1 expression in breast cancer, with variable reports on expression frequency.[23](#his13498-bib-0023){ref-type="ref"}, [31](#his13498-bib-0031){ref-type="ref"}, [32](#his13498-bib-0032){ref-type="ref"}, [33](#his13498-bib-0033){ref-type="ref"}, [34](#his13498-bib-0034){ref-type="ref"} Their therapeutic potential for immunotherapy and the staining homogeneity observed in diverse cohorts led us to investigate the expression of MAGE‐A and NY‐ESO‐1 in our historical cohort of breast cancer patients.

Materials and methods {#his13498-sec-0005}
=====================

Tissue Microarrays (TMAs) and Histopathology Review {#his13498-sec-0006}
---------------------------------------------------

This study made use of the Queensland Follow‐Up (QFU) cohort, a resource comprising formalin‐fixed paraffin‐embedded breast tumours from patients undergoing surgical resection at the Royal Brisbane Women\'s Hospital (RBWH) between 1987 and 1994, with accompanying long‐term (up to 30 years) clinical follow‐up information.[35](#his13498-bib-0035){ref-type="ref"}, [36](#his13498-bib-0036){ref-type="ref"}, [37](#his13498-bib-0037){ref-type="ref"}, [38](#his13498-bib-0038){ref-type="ref"}, [39](#his13498-bib-0039){ref-type="ref"} Ethical approval from the Human Research Ethics Committees of the RBWH and the University of Queensland was obtained prior to the commencement of the study. Tumours were sampled in duplicate on TMAs for biomarker studies, and haematoxylin and eosin‐stained whole tissue sections were available for histopathological review.

The review was conducted by an experienced breast pathologist (S.R.L.; parameters included histological subtype, grade, and the presence of lymphovascular invasion and lymphocytic infiltrate; Table [1](#his13498-tbl-0001){ref-type="table"}). We also considered patient age, tumour size, and lymph node (LN) status (whether disease had spread to the LNs at the time of surgery), extracted from diagnostic pathology reports. We selected a range of breast tumour biomarkers implicated in the prognosis and/or pathobiology of breast cancer: (i) hormone receptors, i.e. ER and PR; (ii) Ki67, a marker of proliferation; and (iii) a range of biomarkers implicated in TNBC, including markers of basal/myoepithelial‐like phenotype \[epidermal growth factor receptor (EGFR) and the high molecular weight cytokeratins (CKs) CK5/6 and CK14\], vimentin (mesenchymal marker), androgen receptor (AR) (can confer luminal‐like intracellular signalling and a luminal‐like phenotype in a proportion of TNBCs with a favourable outcome),[40](#his13498-bib-0040){ref-type="ref"}, [41](#his13498-bib-0041){ref-type="ref"} c‐Kit (associated with primitive, progenitor states[42](#his13498-bib-0042){ref-type="ref"}), p53 (overexpression is associated with genomic instability),[43](#his13498-bib-0043){ref-type="ref"} and mitosis‐independent expression of the dual‐specificity protein kinase TTK (implicated in chromosomal instability and poor clinical outcome.[35](#his13498-bib-0035){ref-type="ref"}

###### 

Association of MAGE‐A and NY‐ESO‐1 expression with histopathological parameters in breast cancer

  MAGE‐A staining:                *n*   \% of cases   *P*‐value   NY‐ESO‐1 staining:   *n*    \% of cases          *P*‐value[a](#his13498-note-0003){ref-type="fn"}                                   
  ------------------------------- ----- ------------- ----------- -------------------- ------ -------------------- -------------------------------------------------- ----- ----- ------ ------ ----- ----------
  Age (years)                                                                                                      Age (years)                                                                        
  \>40                            273   237           36          87                   13     NS                   \>40                                               300   287   13     96     4     NS
  ≤40                             35    27            8           77                   23     ≤40                  38                                                 38    0     100    0            
  *n*                             308                                                         *n*                  338                                                                                
  Grade                                                                                                            Grade                                                                              
  G1                              46    46            0           100                  0      \<0.0001             G1                                                 50    50    0      100    0     0.023
  G2                              176   157           19          89                   11     G2                   170                                                166   4     98     2            
  G3                              140   106           34          76                   24     G3                   134                                                124   10    93     7            
  *n*                             362                                                         *n*                  354                                                                                
  Mitotic score                                                                                                    Mitotic score                                                                      
  1                               43    43            0           100                  0      \<0.0001             1                                                  199   196   3      98     2     0.0255
  2                               154   137           17          89                   11     2                    47                                                 44    3     94     6            
  3                               126   95            31          75                   25     3                    107                                                99    8     93     7            
  *n*                             323                                                         *n*                  353                                                                                
  Histological type                                                                                                Histological type                                                                  
  Ductal NOS                      188   161           27          86                   14     NS                   Ductal NOS                                         207   198   9      96     4     NS
  Lobular/variants                37    35            2           95                   5      Lobular/variants     42                                                 42    0     100    0            
  Mixed ductolobular              30    26            4           87                   13     Mixed ductolobular   32                                                 31    1     97     3            
  Mixed                           30    25            5           83                   17     Mixed ductolobular   31                                                 28    3     90     10           
  Metaplastic                     14    9             5           64                   36     Metaplastic          15                                                 15    0     100    0            
  Special types                   24    20            4           83                   17     Special types        27                                                 26    1     96     4            
  *n*                             323                                                         *n*                  354                                                                                
  Lymph node status                                                                                                Lymph node status                                                                  
  Negative                        97    84            13          87                   13     NS                   Negative                                           102   100   2      98     2     NS
  Positive                        82    69            13          84                   16     Positive             88                                                 83    5     94     6            
  *n*                             179                                                         *n*                  190                                                                                
  Tumour size (mm)                                                                                                 Tumour size (mm)                                                                   
  \< 20                           140   125           15          89                   11     NS                   \<20                                               152   147   5      97     3     NS
  20--50                          121   98            23          81                   19     20--50               132                                                127   5     96     4            
  \>50                            21    18            3           86                   14     \>50                 22                                                 20    2     91     9            
  *n*                             282                                                         *n*                  306                                                                                
  Lymphovascular invasion                                                                                          Lymphovascular invasion                                                            
  Absent                          236   202           34          86                   14     NS                   Absent                                             262   252   10     96     4     NS
  Present                         87    73            14          84                   16     Present              92                                                 88    4     96     4            
  *n*                             323                                                         *n*                  354                                                                                
  Lymphocytic infiltrate                                                                                           Lymphocytic infiltrate                                                             
  Absent                          108   105           3           97                   3      \<0.0001             Absent                                             123   123   0      100    0     NS
  Mild                            145   117           28          81                   19     Mild                 157                                                150   7     96     4            
  Moderate‐severe                 57    42            15          74                   26     Moderate‐severe      61                                                 55    6     90     10           
  *n*                             310                                                         *n*                  341                                                                                
  Central scarring/fibrosis                                                                                        Central scarring/fibrosis                                                          
  Absent                          289   248           41          86                   14     NS                   Absent                                             319   306   13     96     4     NS
  Present                         34    27            7           79                   21                          Present                                            35    34    1      97     3     
  *n*                             323                                                                                                                                 *n*   354                       
  Tumour border                                                                                                    Tumour border                                                                      
  Infiltrative                    281   247           34          88                   12     0.0023               infiltrative                                       310   299   11     96     4     NS
  Pushing                         45    31            14          69                   31     Pushing              44                                                 41    3     93     7            
  *n*                             326                                                         *n*                  354                                                                                
  HR status                                                                                                        Hormone receptor (HR) status                                                       
  Negative                        77    46            31          59.7                 40.3   \<0.0001             Negative                                           68    66    2      97.1   2.9   \<0.0001
  Positive                        244   227           17          93.0                 7.0    Positive             282                                                270   12    95.7   4.3          
  *n*                             321                                                         *n*                  350                                                                                
  ER status                                                                                                        ER status                                                                          
  Positive                        241   225           16          93                   7      \<0.0001             Positive                                           270   268   2      99     1     \<0.0001
  Negative                        83    51            32          61                   39     Negative             85                                                 73    12    86     14           
  *n*                             324                                                         *n*                  355                                                                                
  HER2 status (CISH)                                                                                               HER2 status (CISH)                                                                 
  Negative                        286   244           42          85                   15     NS                   Negative                                           314   301   13     96     4     ns
  Positive                        30    27            3           90                   10     Positive             31                                                 31    0     100    0            
  *n*                             316                                                         *n*                  345                                                                                
  Ki67                                                                                                             Ki67                                                                               
  Negative                        192   177           15          92                   8      \<0.0001             Negative                                           192   188   4      98     2     0.0386
  Positive                        124   93            31          75                   25     Positive             124                                                115   9     93     7            
  *n*                             316                                                         *n*                  316                                                                                
  Basal marker: CK14, CK5, EGFR                                                                                    Basal marker: CK14, CK5. EGFR                                                      
  Negative                        216   199           17          92                   8      \<0.0001             Negative                                           236   235   1      100    0     \<0.0001
  Positive                        87    58            29          67                   33     Positive             91                                                 78    13    86     14           
  *n*                             303                                                         *n*                  327                                                                                
  Vimentin                                                                                                         Vimentin                                                                           
  Negative                        284   253           31          89                   11     \<0.0001             Negative                                           316   308   8      97     3     0.0016
  Positive                        38    21            17          55                   45     Positive             38                                                 32    6     84     16           
  *n*                             322                                                         *n*                  354                                                                                
  Androgen receptor                                                                                                Androgen receptor                                                                  
  Negative                        35    19            16          54                   46     \<0.0001             Negative                                           38    30    8      79     21    \<0.0001
  Positive                        278   248           30          89                   11     Positive             305                                                300   5     98     2            
  *n*                             313                                                         *n*                  343                                                                                

CISH, chromogenic *in‐situ* hybridisation; CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MAGE, melanoma‐associated antigen; NOS, not otherwise specified; NS, not significant; NY‐ESO‐1, New York Esophageal Squamous Cell Carcinoma‐1. st.

Chi‐square test or Fisher\'s exact test.

John Wiley & Sons, Ltd

Immunohistochemical (IHC) Analysis {#his13498-sec-0007}
----------------------------------

Analysis of the CTAs were performed by staining the QFU TMA slides with antibodies against MAGE‐A (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc‐20034, 1:500 dilution), NY‐ESO‐1 (Santa Cruz Biotechnology; sc‐53869, 1:30 dilution), p53 (Dako, Santa Clara, CA, USA; M7001, 1:150 dilution), c‐Kit (Dako; A4502, 1:1000 dilution), TTK (Abcam, Cambridge, UK; ab11108, 1:100 dilution), HER2 (Dako; A0485, 1:200 dilution), ER (Novocastra, Newcastle upon Tyne, UK; NCL‐L‐ER‐6F11, 1:100 dilution), PR (Novocastra; NCL‐L‐PGR‐312, 1:200 dilution), vimentin (Dako; M0725, 1:400 dilution), AR (Dako; M3562, 1:50 dilution) and Ki67 (Dako; M724001‐2, 1:200 dilution) with the MACH 1 Universal HRP‐Polymer (Biocare Medical; (Pacheco, CA, USA; Cat. no. M1U539 G, L10) or Vectastain Universal ABC (Vector Laboratories, Burlingame, CA, USA) kit. Slides were scanned with the Aperio ScanScope T2 digital system (Buffalo Grove, IL, USA), and core images were then segmented into individual images for scoring (Aperio Spectrum TMA module).

Samples were assessed in a blinded manner by two observers (A.P. and P.K.dC). For MAGE‐A and NY‐ESO‐1, scoring was based purely on intensity, owing to its homogeneity of staining in the tissue cores. A score in a range of 0--3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong) was assigned for each cellular compartment---cytoplasm and nucleus. However, the majority of the cases (65%) expressed CTAs homogeneously throughout the tumour compartment of duplicate cores, and there were no obvious subcellular expression patterns. Hence, cytoplasmic and nuclear component scoring were not considered separately for further analysis. Tumour cell percentage staining was subsequently stratified as either \>75% or \<75%, as this adequately described the positive cases. IHC analysis was performed for the markers, the results for some of which have been published previously.[35](#his13498-bib-0035){ref-type="ref"}, [36](#his13498-bib-0036){ref-type="ref"}, [38](#his13498-bib-0038){ref-type="ref"}, [39](#his13498-bib-0039){ref-type="ref"} The cut‐off value for HER2 positivity was based on a silver *in‐situ* hybridisation (SISH) score of \>6 and an IHC score of 3+ if SISH was unsuccessful. Once HER2 positivity had been determined, ER status and PR status were examined; staining of ≥1% of the tumour cell nuclei was considered to be positive. After scoring for ER positivity if the sample was negative for both ER/PR and HER2, it was assigned to the TN subtype. For distinction between TN, basal‐like, and non‐basal, if ≥1% of tumour cells were positive for either EGFR or CK14 or CK5/6, the tumour was considered to be TN basal‐like. However, with relevance to the clinical context, TN/basal‐like is not a clinically defined subtype, and we therefore assigned any tumours that fell into the TN category to the TN group.

Once HER2 status and ER status had been determined, Ki67 expression was scored high if staining was observed in 10% of the tumour cell nuclei, and low if it was observed in \<10% of the tumour cell nuclei. Biomarkers such as TTK and c‐Kit were scored purely on intensity, owing to the homogeneity of staining in the tissue cores. A score in a range of 0--3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong) was assigned. Scoring for p53, vimentin and AR was based on an IHC score, which was derived by multiplying the intensity and percentage of the tumour cell staining. It was further stratified into a binary scoring system, i.e. 0--1 (\<60 = 0/negative and \>60 = 1/positive for p53; \>0 = 1/positive for AR and vimentin).

Statistical analysis was performed with [prism]{.smallcaps} (v7). Associations between MAGE‐A, NY‐ESO‐1 and clinicopathological parameters were evaluated with the chi‐square test and Fisher\'s exact test. Relationships with breast cancer‐specific survival were investigated with Kaplan--Meier analysis, with log‐rank tests being used to assess significance. *P*‐values of \<0.05 were considered to be significant.

Results {#his13498-sec-0008}
=======

Cohort Demographics and Clinicopathology {#his13498-sec-0009}
----------------------------------------

Among the 367 cases, the median patient age at diagnosis was 59 years, the median follow‐up was 5.2 years, and the median follow‐up of patients who were alive was 21.5 years. These cases were collected between 1987 and 1994. Most of the cases were grade 2 (49%), and LN status was available for 56% of the cohort (27% LN‐positive; 29% LN‐negative) (Figure [1](#his13498-fig-0001){ref-type="fig"}A). Invasive ductal carcinoma (IDC) was the major histological subtype (58%), followed by lobular variants (12%), mixed histologies (ductolobular, 9%; others collectively, 9%), metaplastic (5%), and other special types (collectively, 7%; Figure [1](#his13498-fig-0001){ref-type="fig"}A). IHC staining showed that 75% of the cohort were ER‐positive, and SISH analysis identified *ERBB2* amplification in 10% of cases.

![**A**, Distribution of the Queensland Follow‐Up patient population according to: grade, lymph node involvement, histological subtype, oestrogen receptor positivity, HER2 status, and various prognostic subtypes. **B**,**C**, Representative images of MAGE‐A and NY‐ESO‐1 staining on breast tumour tissue microarray cores, shown at low and high magnification. **D**, Concomitant expression of MAGE‐A and NY‐ESO‐1. **E**, Proportion of MAGE‐A‐positive and NY‐ESO‐1‐positive tumours expressing the respective antigens in \>75% of cells within duplicate cores.](HIS-73-68-g001){#his13498-fig-0001}

Cases were also categorised according to their expression of a panel of prognostic biomarkers: ER, PR, HER2, Ki67, and expression of EGFR and/or high molecular weight cytokeratins (CK5/6 and CK14), which are associated with a basal‐like phenotype. According to this scheme,[35](#his13498-bib-0035){ref-type="ref"} the majority of the cohort was categorised as ER‐positive/Ki67‐low (65%), followed by TN/basal‐like (15%), HER2‐positive (10%), ER‐positive/Ki67‐high (7%) and TN/non‐basal (3%) (Figure [1](#his13498-fig-0001){ref-type="fig"}A).

Expression of MAGE‐A and NY‐ESO‐1 in Invasive Breast Cancer {#his13498-sec-0010}
-----------------------------------------------------------

MAGE‐A and NY‐ESO‐1 showed homogeneous staining, with positivity in both cytoplasmic and nuclear tumour cell compartments in 13% (*n* = 48) and 3.8% (*n* = 14) of cases, respectively (Figure [1](#his13498-fig-0001){ref-type="fig"}B--D). CTA staining was relatively homogeneous, with \>75% of tumour cells being stained in the majority of the MAGE‐A‐positive (83%) and NY‐ESO‐1‐positive (85%) cases (Figure [1](#his13498-fig-0001){ref-type="fig"}E). This criterion was employed as a threshold to note homogeneity, and not as a cut‐off for positivity. Interestingly, 12 of the 14 NY‐ESO‐1‐positive cases coexpressed MAGE‐A (Figure [1](#his13498-fig-0001){ref-type="fig"}D; *P* = 2.06 × 10^−9^). Analysis of clinicopathological parameters showed that expression of both CTAs was associated with Ki67 expression and grade (driven mostly by the mitotic score component; Table [1](#his13498-tbl-0001){ref-type="table"}). This was underpinned by strong enrichment of expression in TN tumours (86% of which were TN/basal‐like for MAGE‐A, and all of which were TN/basal‐like for NY‐ESO‐1 (Figure [2](#his13498-fig-0002){ref-type="fig"}Ai,ii). Taking advantage of data generated as part of previous QFU cohort studies,[35](#his13498-bib-0035){ref-type="ref"}, [36](#his13498-bib-0036){ref-type="ref"}, [37](#his13498-bib-0037){ref-type="ref"}, [38](#his13498-bib-0038){ref-type="ref"}, [39](#his13498-bib-0039){ref-type="ref"} we further examined the phenotypic features of MAGE‐A‐expressing and NY‐ESO‐1‐expressing TNBCs, and found positive associations with c‐Kit, p53, and mitosis‐independent TTK expression (Figure [2](#his13498-fig-0002){ref-type="fig"}B). The CTAs (particularly NY‐ESO‐1) were also associated with expression of vimentin (a marker of mesenchymal differentiation), and were inversely associated with AR expression (Table [1](#his13498-tbl-0001){ref-type="table"}), although these associations did not reach statistical significance within the TN group (not shown).

![**A**,**B**, Chi‐square or Fisher\'s exact test analysis of associations between expression of MAGE‐A/NY‐ESO‐1 and clinical diagnostic or experimental biomarkers (c‐Kit, p53, and TTK1).](HIS-73-68-g002){#his13498-fig-0002}

Expression of MAGE‐A and NY‐ESO‐1 in Breast Cancer is Not Associated With Survival {#his13498-sec-0011}
----------------------------------------------------------------------------------

The median overall survival time of all cases in this present study was 13.6 years. According to Kaplan--Meier survival analysis, MAGE‐A‐positive cases within the whole cohort showed a 40% decrease in breast cancer‐specific survival (BCSS) at 25 years (Figure [3](#his13498-fig-0003){ref-type="fig"}A), and MAGE‐A‐positive cases within the TN group showed a 35% decrease in BCSS at 5 years (Figure [3](#his13498-fig-0003){ref-type="fig"}C), which was not significantly different from the MAGE‐A‐negative cases. NY‐ESO‐1‐positive cases showed a trend towards a poorer outcome (Figure [3](#his13498-fig-0003){ref-type="fig"}B), but there was no difference after accounting for TN status (Figure [3](#his13498-fig-0003){ref-type="fig"}D).

![Kaplan--Meier survival analysis of the whole Queensland Follow‐Up cohort (**A**,**B**) or triple‐negative breast cancer (TNBC) cases (**C**,**D**) according to MAGE‐A and NY‐ESO‐1 expression. For TNBC, the analysis focuses on the first 5 years after diagnosis, which is the period that is most determinant of long‐term outcome. \[Colour figure can be viewed at [wileyonlinelibrary.com](http://www.wileyonlinelibrary.com/)\]](HIS-73-68-g003){#his13498-fig-0003}

Discussion {#his13498-sec-0012}
==========

We investigated the expression of MAGE‐A and NY‐ESO‐1 in invasive breast cancer, and found prevalent expression within the TN group. Previous reports have shown variable expression of MAGE‐A and NY‐ESO‐1, ranging between 17% and 74%, and between 2% and 40%, respectively,[31](#his13498-bib-0031){ref-type="ref"}, [44](#his13498-bib-0044){ref-type="ref"} and the expression levels of both were higher in TNBC,[31](#his13498-bib-0031){ref-type="ref"}, [44](#his13498-bib-0044){ref-type="ref"}, [45](#his13498-bib-0045){ref-type="ref"}, [46](#his13498-bib-0046){ref-type="ref"}, [47](#his13498-bib-0047){ref-type="ref"}, [48](#his13498-bib-0048){ref-type="ref"} which corroborates our findings. Taking advantage of the large pre‐existing dataset on experimental biomarkers in the QFU cohort, we found that the CTAs are expressed most prevalently in the TN tumours showing salient features of poor differentiation/primitive phenotype, proliferation, and genomic instability. This was indicated by coexpression of c‐Kit and TTK, and overexpression of p53. In addition, we found that these CTAs were expressed concomitantly and in the majority of the cells within a tumour, suggesting that they have favourable features as cancer vaccine targets. Our study strengthens the rationale for targeting CTAs to broaden the therapeutic options for TNBC.

Mutations in p53 can result in a stable non‐functional protein that accumulates in the nucleus, and that gives rise to an IHC phenotype mimicking overexpression;[43](#his13498-bib-0043){ref-type="ref"}, [49](#his13498-bib-0049){ref-type="ref"} thus, p53 overexpression in cancer is a surrogate for functional abrogation. CIN and aneuploidy are interrelated and are crucial hallmarks of cancer, which is partly contributed to by inadequacy of p53.[50](#his13498-bib-0050){ref-type="ref"}, [51](#his13498-bib-0051){ref-type="ref"}, [52](#his13498-bib-0052){ref-type="ref"}, [53](#his13498-bib-0053){ref-type="ref"}, [54](#his13498-bib-0054){ref-type="ref"}, [55](#his13498-bib-0055){ref-type="ref"} This promotes aberrant DNA damage repair and augments mutagenesis.[56](#his13498-bib-0056){ref-type="ref"} Through association with p53 coexpression, our findings imply that NY‐ESO‐1‐positive tumours reflect these chromosomal abnormalities, and have a proliferative advantage. However, we observed no association between MAGE‐A and p53, which, perhaps, could be attributed to MAGE‐A inhibiting its function;[57](#his13498-bib-0057){ref-type="ref"} one possible suggested mechanism is blocking of the interaction between p53 and chromatin, thus making p53 unable to regulate tumour cell proliferation and apoptosis.[57](#his13498-bib-0057){ref-type="ref"}, [58](#his13498-bib-0058){ref-type="ref"} Furthermore, we found a strong association between MAGE‐A expression and mitosis‐independent expression of the spindle assembly checkpoint protein TTK, which is crucial for chromosomal alignment and centrosome duplication, and is a marker for CIN in TNBC.[35](#his13498-bib-0035){ref-type="ref"}, [59](#his13498-bib-0059){ref-type="ref"}, [60](#his13498-bib-0060){ref-type="ref"}

Re‐expression of CTAs in cancer is thought to give cancer cells stem cell‐like properties.[61](#his13498-bib-0061){ref-type="ref"} Interestingly, we found striking coexpression of both CTAs with the mammary luminal progenitor marker c‐Kit (Figure [2](#his13498-fig-0002){ref-type="fig"}Bi,ii), and enrichment with vimentin (Table [1](#his13498-tbl-0001){ref-type="table"}), suggesting that these tumours are in relatively primitive states of differentiation.[62](#his13498-bib-0062){ref-type="ref"} Basal‐like breast cancers often show luminal progenitor‐like phenotypes, and may even originate from this cell type in the premalignant breast.[42](#his13498-bib-0042){ref-type="ref"} Therefore, this striking coexpression could be part of the association with the basal‐like phenotype (Table [1](#his13498-tbl-0001){ref-type="table"}). This strong correlation might also indicate a programmed state of dedifferentiation involving multiple stem cell markers, whereby a demethylation programme drives the expression of these CTAs, as is evident in ovarian and colon cancer.[63](#his13498-bib-0063){ref-type="ref"}, [64](#his13498-bib-0064){ref-type="ref"}

If cancer vaccine or CAR T‐cell therapies are to be implemented for treatment in certain cases, efficacy would be determined, in part, by antigen abundance and heterogeneity. An extensive IHC analysis of the expression of eight CTAs in 454 IDCs revealed frequent coexpression in ER‐positive as compared with ER‐negative tumours,[47](#his13498-bib-0047){ref-type="ref"} consistent with our findings on MAGE‐A and NY‐ESO‐1 coexpression. This raises the possibility that therapies simultaneously targeting multiple CTAs may elicit more efficient antitumour responses than single‐antigen approaches. In terms of expression heterogeneity, we found that the majority of cases expressed MAGE‐A and NY‐ESO‐1 in \>75% of tumour cells within duplicate cores, which is also a potentially favourable feature in terms of therapeutic use. To maximise the efficacy of vaccination‐based strategies, it would be informative to analyse the distribution of multiple 'actionable' CTAs within individual tumours in a larger cohort, in order to identify combinations that could achieve the greatest breadth of coverage.

Immunotherapy is an attractive strategy to target TNBC, especially in patients with minimal residual disease after neoadjuvant chemotherapy, because of their statistically poor prognosis.[46](#his13498-bib-0046){ref-type="ref"}, [48](#his13498-bib-0048){ref-type="ref"} Analysing MAGE‐A and NY‐ESO‐1 expression in post‐neoadjuvant chemotherapy surgical samples may therefore aid in recognising patients who are suitable for vaccination strategies. Interestingly, adoptive T‐cell therapy targeting MAGE‐A3 has shown promise in the metastatic setting,[65](#his13498-bib-0065){ref-type="ref"} and another trial is ongoing (Identifier no. NCT02111850).[66](#his13498-bib-0066){ref-type="ref"} We hypothesise that CTAs may be expressed more frequently in the chemoresistant cells selected after neoadjuvant therapy, owing to their association with features that promote clonal selection (primitive phenotype, high proliferation, and CIN). Features of high proliferation, evasion of apoptosis, and a primitive/stem‐like state, which is considered to be an epithelial--mesenchymal transition state, perhaps confer chemoresistance to these cells, as is evident in multiple myeloma.[67](#his13498-bib-0067){ref-type="ref"}

Finally, our study was performed on a small number of TN tumours, so our findings are worth following up in a larger cohort. Nonetheless, given the promising benefits of immunotherapy for this group of patients with currently limited interventional strategies, it provides the rationale for targeting CTAs in TNBC.
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